Development and Sales of Foods with Function Claims
First written in FY2016. 15 of 29 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In 2025, we also obtained approval as a Food for Specified Health Uses with a disease-risk-reduction claim for the fish sausage “DHA入りリサーラソーセージACE(エース),” which promotes a risk-reduction effect for atherosclerotic disease.」
Following the previous fiscal year, the company advanced its DHA- and EPA-based Foods for Specified Health Uses with disease-risk-reduction claims by obtaining approval in 2025 for the new product “DHA入りリサーラソーセージACE.” - 2026-05-11AdvancedEarnings presentation
「The Company aims to increase the value added and sales of existing products by obtaining function claims labeling.」
Obtaining function claims labeling was specified as a means of increasing the value added and sales of existing products in the following fiscal year. - FY2025AdvancedAnnual report
「In 2024, we launched the fish sausage “DHA入りリサーラソーセージω(オメガ),” the first product in Japan to receive approval as a Food for Specified Health Uses with a disease-risk-reduction claim, based on its potential to reduce the risk of cardiovascular disease, with DHA and EPA as the functional ingredients.」
For a Food for Specified Health Uses with a disease-risk-reduction claim using DHA and EPA, the company obtained Japan’s first approval and proceeded to launch the product. - FY2024-Q3RestatedAnnual report
「The Fine Chemicals Unit posted lower revenue and profit due to customers holding back on purchases following a review of how the Foods with Function Claims system is operated, as well as higher raw-material costs resulting from Peru’s anchovy fishing ban, among other factors.」
Trading partners’ purchase restraint following the review of the operation of the Foods with Function Claims system and higher raw-material costs due to the anchovy fishing ban continue to be cited as factors behind lower revenue and profit in the functional-products business. - FY2024-Q2Lower revenue and profit due to a review of the operation of the Foods with Function Claims system and other factorsAnnual report
「The Fine Chemicals Unit posted lower revenue and profit due to customers holding back on purchases following a review of how the Foods with Function Claims system is operated, as well as higher raw-material costs resulting from Peru’s anchovy fishing ban, among other factors.」
Customer purchase restraint following the review of the operation of the Foods with Function Claims system and higher raw-material costs due to Peru’s anchovy fishing ban were cited as factors behind lower revenue and profit in the functional-products business. - FY2024-Q1RestatedAnnual report
「The Fine Chemicals Unit’s sales for health foods remained firm and progressed as planned, but the unit posted lower revenue and profit because certain products had recorded substantial sales in the same period of the previous year.」
Sales for health foods remained firm and progressed as planned, but the Fine Chemicals Unit posted lower revenue and profit due to the pullback from temporarily substantial sales in the same period of the previous year. - FY2023AdvancedAnnual report
「As the second product in the series, we developed a product design in which our refined fish oil was added to tuna tataki to ensure that it contained at least the specified amounts of DHA and EPA. In April 2023, we began selling “新鮮プレミアム 鮪たたき,” claiming an effect of reducing triglycerides.」
For a Food with Function Claims, the company developed a tuna-tataki product using refined fish oil and began sales in April 2023. - FY2023-Q1RestatedAnnual report
「The Fine Chemicals Unit posted lower revenue because shipments of active pharmaceutical ingredients were delayed, but profit increased on strong sales for health foods, centered on DHA and EPA.」
The company continues to report strong sales for health foods, centered on DHA and EPA, but does not disclose the number of new notifications or product launches. - FY2022AdvancedAnnual report
「Clinical trials confirmed that the product has functions that help improve sleep quality or energy and vitality, and its notification as a Food with Function Claims was accepted.」
The company reported clinical trials, acceptance as a Food with Function Claims, and product development for a supplement based on salmon roe oil derived from an unused resource. - FY2022-Q2RestatedAnnual report
「The Chemicals Unit posted higher revenue as sales of DHA and EPA and chondroitin increased, but profit declined because freeze-dried products were significantly affected by the pullback from the previous year’s surge in demand.」
The company continues to report growth in sales of functional products, including DHA and EPA, but does not identify any new milestones, such as additional notifications or new-product launches. - FY2022-Q1RestatedAnnual report
「The Chemicals Unit posted higher revenue and profit as sales of DHA and EPA and pharmaceutical-grade chondroitin remained strong.」
The company continues to report strong sales of functional products, including DHA and EPA, as well as higher revenue and profit. - FY2021AdvancedAnnual report
「As part of an initiative with Beisia Co., Ltd., we considered selling products in the seafood section as Foods with Function Claims that reduce triglycerides. The notification was accepted, and sales began at Beisia stores in April 2021.」
For Foods with Function Claims, the company proceeded to a specific sales rollout, beginning sales at Beisia stores. It is also considering expanding the range of fish species. - FY2021-Q3Higher profit driven by increased sales of DHA, EPA and other productsAnnual report
「The Chemicals Unit posted higher profit despite revenue remaining broadly unchanged from the previous year, as sales of DHA and EPA products and freeze-dried products increased.」
Sales of DHA and EPA products and freeze-dried products increased. Although revenue was broadly unchanged from the previous year, the Chemicals Unit posted higher profit. - FY2021-Q2Increased stay-at-home demand for freeze-dried products and pullback in DHA and EPA salesAnnual report
「The Chemicals Unit posted lower revenue because, unlike in the same period of the previous year, there were no concentrated DHA and EPA sales. However, sales of freeze-dried products increased on higher stay-at-home demand during the COVID-19 pandemic, resulting in higher profit.」
Revenue declined due to the pullback from concentrated DHA and EPA sales in the same period of the previous year, while freeze-dried product sales increased on stay-at-home demand during the COVID-19 pandemic, resulting in higher profit. - FY2021-Q1DHA and EPA shipment pullback and freeze-dried plant shutdownAnnual report
「The Chemicals Unit posted lower revenue and profit because DHA and EPA shipments had been temporarily concentrated in the same period of the previous year, while operations at the freeze-dried plant in China were temporarily suspended due to the impact of COVID-19.」
The Chemicals Unit posted lower revenue and profit due to the pullback from concentrated DHA and EPA shipments in the same period of the previous year and the temporary suspension of operations at the freeze-dried plant in China. No change or withdrawal of the functional-foods business policy is reported. - FY2020-Q3RestatedAnnual report
「The Chemicals Unit posted higher revenue and profit as sales of DHA and EPA and freeze-dried products remained strong.」
The company continues to report strong sales of DHA and EPA and freeze-dried products, as well as higher revenue and profit. No new notification or launch figures are disclosed. - FY2020-Q2RestatedAnnual report
「The Chemicals Unit posted higher revenue and profit as sales of DHA and EPA and freeze-dried products remained strong.」
The company continues to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system. No new notification or launch figures are disclosed. - FY2019-Q3RestatedAnnual report
「The Chemicals Unit posted higher revenue and profit as sales of freeze-dried products and DHA and EPA remained strong, benefiting from the Foods with Function Claims system.」
The company continues to report strong DHA and EPA sales and higher revenue and profit against the backdrop of the Foods with Function Claims system. No new notification or launch figures are disclosed. - FY2019-Q2RestatedAnnual report
「The Chemicals Unit posted higher revenue and profit as sales of freeze-dried products and DHA and EPA remained strong, benefiting from the Foods with Function Claims system.」
The company continues to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system, but does not disclose the number of new notifications or launches. - FY2019-Q1RestatedAnnual report
「The Chemicals Unit posted higher revenue as sales of freeze-dried products and DHA and EPA remained strong, benefiting from the Foods with Function Claims system. Profit also increased, with higher DHA and EPA revenue contributing to the gain.」
The company continues to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system, but does not disclose the number of new notifications or launches. - FY2018AdvancedAnnual report
「To overcome this hurdle, we conducted year-round surveys of the DHA and EPA content of kampachi, a farmed fish widely known as a representative aquaculture species, and implemented specification controls. In January 2018, this led to the acceptance of the first notification for a Food with Function Claims in the fresh-food category among fishery products.」
Through year-round surveys and specification controls, the company obtained acceptance of the first notification for farmed kampachi as a fresh fishery product with a function claim. - FY2018-Q3RestatedAnnual report
「The Chemicals segment’s revenue was broadly unchanged from the previous year, as it adjusted sales of protamine and DNA due in part to raw-material shortages caused by poor salmon catches. However, profit increased as DHA and EPA sales remained strong, benefiting from the Foods with Function Claims system.」
While the segment was affected by raw-material shortages caused by poor salmon catches, it continued to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system. - FY2018-Q2RestatedAnnual report
「The Chemicals segment reported strong DHA and EPA sales, benefiting from the Foods with Function Claims system, but posted lower revenue and profit due to a decline in health food exports.」
The company continues to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system, but does not disclose the number of new notifications or launches. - FY2018-Q1RestatedAnnual report
「Although the Chemicals segment reported lower revenue due to a decline in health food exports, profit increased as sales of DHA and EPA remained strong, benefiting from the Foods with Function Claims system, as they had the previous year.」
The company continues to report strong DHA and EPA sales against the backdrop of the Foods with Function Claims system, but does not disclose the number of new notifications or product launches. - FY2017AdvancedAnnual report
「Based on the results of our many years of research into DHA and EPA, health-related ingredients derived from fish oil, we moved quickly to develop Foods with Function Claims. As a result, we successively developed the industry’s and categories’ first Foods with Function Claims. As of April 2017, the Consumer Affairs Agency had accepted notifications for a total of 12 products: 7 products containing DHA and EPA as the functional ingredients and claiming to reduce triglycerides, and 5 products containing DHA as the functional ingredient and supporting memory function. Six of these products have already been launched.」
The number of products with accepted notifications increased from 11 to 12, and 6 products are reported as having been launched. The company is proceeding with notifications for additional products and considering materials other than DHA and EPA. - FY2017-Q3ReframedAnnual report
「The company has pursued its growth strategy, including expanding the fully farmed tuna business, increasing earnings in global operations, and launching new products that provide new value.」
The planned new-product initiative has been generalized from the previous wording, “launch of new Foods with Function Claims,” to “launch of new products that provide new value.” Meanwhile, the Chemicals segment reports strong DHA and EPA sales and increased exports of cosmetics and health foods. - FY2017-Q2RestatedAnnual report
「The Chemicals segment posted higher revenue and profit, driven by strong sales of DHA and EPA products amid the tailwind from the Foods with Function Claims system, as well as increased exports of cosmetics and health foods to Hong Kong in response to rising demand in the Chinese market.」
Sales of DHA and EPA products under the Foods with Function Claims system and exports to Hong Kong for the Chinese market are reported to remain strong. - FY2017-Q1RestatedAnnual report
「The Chemicals segment posted higher revenue and profit, driven by strong sales of DHA and EPA products amid the tailwind from the Foods with Function Claims system, as well as increased exports of cosmetics and health foods to Hong Kong in response to rising demand in the Chinese market.」
Strong sales of DHA and EPA products against the backdrop of the Foods with Function Claims system are reported, but no new volume milestone, such as the number of new products, is indicated. - FY2016First statedAnnual report
「As of April 2016, the Consumer Affairs Agency had accepted notifications for a total of 11 products: 6 products containing DHA and EPA as functional ingredients and claimed to help lower triglycerides, and 5 products containing DHA as a functional ingredient and claimed to support memory function. Of these, 6 products had already been launched.」
Based on DHA and EPA research, specific progress is reported in the acceptance of notifications for 11 products and the launch of 6 products.